Novartis Scores Another CSU Success With Remibrutinib
Oral BTK Inhibitor Controls Itching And Hives In Phase IIb
The Swiss group believes that remibrutinib, as well as its investigational IgE antibody ligelizumab, will complement standard of care Xolair and help it build a strong franchise for chronic spontaneous urticaria.
You may also be interested in...
"We are definitely worried," Tschudin said about some US drug price reform proposals. She also spoke with Scrip about competitive rebating and new growth opportunities for anchor brands.
Analysts who felt Sanofi paid way over the odds when splashing out $3.7bn to buy Principia last year will be feeling justified in that stance after one of the oral BTK inhibitors acquired, rilzabrutinib, proved to be no more effective than placebo in a Phase III trial.
Novartis and Roche's Xolair was approved as a treatment for hives in 2014 and has transformed treatment for patients with severe symptoms. New data on the former's new IgE inhibitor suggest that a more effective drug could be on the way.